YD Bio Enters into MOU to Merge with EG BioMed to Expand Global Medical Industry Footprint

(L-R) Edmund Hen (CFO, YD Bio), Ethan Shen, PhD (Chairman & CEO of YD Bio), Ruo-Kai Lin (Chief of R&D at EG BioMed), Dr. Ansar Muhamad (Product Engineer), and Grace Liu (R&D Marketing Manager, EG BioMed).

YD Bio Limited (Nasdaq: YDES), the U.S. parent company of YD Bio Co., Ltd., officially announced on January 13 its merger with IRIGEN Biotech Co., Ltd. This strategic move aims to establish a fully integrated, data-driven diagnostic and therapeutic platform.

Dr. Shen, Chairman and CEO of YD Bio, stated that prior to the merger, IRIGEN’s products had already received clinical approval from major medical centers in Taipei. These solutions are currently being integrated into hospital workflows to assist clinicians in monitoring treatment responses, disease progression, and recurrence.

The early-stage clinical adoption by medical institutions serves to validate both the clinical and economic value of the technology, providing a solid evidence-based foundation for future expansion across more healthcare facilities. Dr. Shen further noted that broader clinical adoption is expected to drive diagnostic revenue growth and provide critical insights for the research and development of subsequent therapeutic products.

EG BioMed integrates diagnostic technologies, therapeutic methods, real-world clinical data, and AI analytical capabilities. The company is dedicated to mitigating R&D risks and accelerating the time-to-market for new products; however, actual outcomes will depend on execution performance, regulatory compliance, and market feedback.

YD Bio Limited is a biotechnology company focused on advancing clinical trials, drug development, cancer diagnostics, and stem cell and exosome therapies. The company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D operations, Ever-Top is a prominent supplier of clinical trial medications and has expanded into the development and sale of related ancillary products.

Media Coverage

Yahoo News  https://pse.is/8ldpux

udn.com (United Daily News)  https://udn.com/news/story/7241/9262484

Taiwan News Post  https://newstaiwan.net/2026/01/13/399116/